Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CollPlant Biotechnologies (CLGN) Operating Income (2017 - 2025)

CollPlant Biotechnologies filings provide 9 years of Operating Income readings, the most recent being -$3.2 million for Q4 2025.

  • On a quarterly basis, Operating Income rose 20.73% to -$3.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.8 million, a 936.07% decrease, with the full-year FY2025 number at -$11.5 million, up 33.44% from a year prior.
  • Operating Income hit -$3.2 million in Q4 2025 for CollPlant Biotechnologies, up from -$3.5 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $10.0 million in Q1 2021 to a low of -$5.1 million in Q4 2023.
  • Median Operating Income over the past 5 years was -$3.1 million (2021), compared with a mean of -$579100.0.
  • The widest YoY moves for Operating Income: up 687.35% in 2021, down 421625.89% in 2021.
  • CollPlant Biotechnologies' Operating Income stood at -$3.8 million in 2021, then dropped by 22.92% to -$4.7 million in 2022, then decreased by 8.38% to -$5.1 million in 2023, then increased by 21.59% to -$4.0 million in 2024, then rose by 20.73% to -$3.2 million in 2025.
  • The last three reported values for Operating Income were -$3.2 million (Q4 2025), -$3.5 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.